Article Text

FRI0520 Improved patient-reported outcomes in psoriatic arthritis patients treated with abatacept: results from a phase iii trial
  1. V Strand1,
  2. E Alemao2,
  3. T Lehman2,
  4. A Johnsen2,
  5. S Banerjee2,
  6. H Ahmad2,
  7. P Mease3
  1. 1Stanford University, Stanford
  2. 2Bristol-Myers Squibb, Princeton
  3. 3Swedish Medical Center and University of Washington, Seattle, United States


Background In the Phase III ASTRAEA study (NCT01860976), abatacept (ABA) significantly increased ACR20 responses, with benefits on other musculoskeletal symptoms in patients (pts) with active psoriatic arthritis (PsA).1 As PsA impacts HRQoL, assessing treatment (tmt) effect using patient-reported outcomes (PROs) is important.

Objectives To explore the effect of ABA tmt using PROs in intent-to-treat and post hoc analyses of ASTRAEA.

Methods Pts were randomized (1:1) to SC ABA 125 mg weekly or placebo (PBO) for 24 weeks (W). At W16, pts without ≥20% improvement in joint counts started open-label ABA. Adjusted mean changes from baseline (BL) to W16 (all pts) and W24 (responder analysis) in Short Form-36 (SF-36; physical and mental component summary [PCS, MCS] and individual domains using spydergrams), pain VAS and HAQ-DI scores, Dermatology QoL Index (DLQI) and FACIT-Fatigue scale (FACIT-F) were evaluated in the total population and subgroups stratified by BL CRP level and prior TNFi use. Proportions of pts reporting improvements ≥minimal clinically important difference (MCID) in SF-36 summary (≥2.5) and domain (≥5.0), FACIT-F (≥40) and HAQ-DI (<–0.22) scores and ≥normative values in SF-36 summary (≥50) and domains, FACIT-F (<40) and HAQ-DI (<0.5) at W16 were analysed in the total population.

Results In the total population, improvements in all PROs were numerically greater for ABA (n=213) vs PBO (n=211) at W16 and W24 and significant for SF-36 PCS at W16 and HAQ-DI at W24 (Table). At W16, improvements in all SF-36 domains were numerically greater with ABA, and significant for physical function, bodily pain and vitality. A higher proportion of pts receiving ABA vs PBO reported improvements ≥MCID in SF-36 PCS, MCS, SF-36 domains, FACIT-F, HAQ-DI (Fig) and DLQI (not shown) at W16. The proportion of pts whose scores were ≥normative values at W16 was higher with ABA vs PBO in SF-36 PCS, MCS, FACIT-F and HAQ-DI scores. At W24, improvements in SF-36 domain scores accrued in both groups, with numerical differences in favour of ABA except in social function. Improvements in PROs were greater with ABA tmt in BL CRP>upper limit of normal (ULN) vs CRP≤ULN and in TNFi-naïve vs -exposed subpopulations.

Table 1.

Change from Baseline in PROs at 16 and 24 Weeks

Conclusions Abatacept treatment improved many PROs in pts with active PsA, with larger benefits in the CRP>ULN and TNF-naïve subpopulations.


  1. Mease P, et al. Arthritis Rheumatol 2016;68(suppl 10): [Abstract 1041].


Disclosure of Interest V. Strand Consultant for: AbbVie, Amgen Corporation, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Corrona, Crescendo/Myriad Genetics, EMD Serono, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB, E. Alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, T. Lehman Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, A. Johnsen Employee of: Bristol-Myers Squibb, S. Banerjee Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, H. Ahmad Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, P. Mease Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, Genentech, Janssen, Novartis, Pfizer, UCB

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.